Usted buscó: attakker (Danés - Inglés)

andel med attakker
0.71 (0.55, 0.93)

andel af forsøgsdeltagere med attakker
proportion of subjects relapsed

(område) attakker i forudgående 12
(range) relapses in previous 12 months,

procent patienter, der er fri for attakker
percentage of relapse-free patients

gennemsnitligt antal attakker i de sidste 3 år
mean number of relapses within the past 3 years

attakker (relapser) i perioder uden symptomer.
attacks (relapses) within periods with no symptoms.

hovedmålet for behandlingens virkning var antallet af attakker.
the main measures of effectiveness was the number of exacerbations.

procent med ≥ 2 attakker i året forud for studiet
percent ≥ 2 relapses in the year prior to study

attakker i forudgående 12 måneder ,median (område)
relapses in previous 12 months, median (range)

lemtrada helbreder ikke ms, men kan nedsætte antallet af attakker.
lemtrada does not cure ms, but it can reduce the number of ms relapses.

hovedmålet for behandlingens virkning var reduktionen i antallet af attakker.
the main measure of effectiveness was the reduction in the number of relapses.

avonex forsinker progressionen af invaliditeten og reducerer antallet af attakker,
avonex slows the progression of disability and reduces the number of relapses.

patienterne havde haft mindst to attakker inden for de foregående to år.
the patients had experienced at least two relapses in the previous two years.

dette er den type ms, hvor patienten får attakker i perioder uden symptomer.
this is the type of ms where the patient has attacks (relapses) in between periods with no symptoms.

forbigående neurologiske symptomer, der kan ligne attakker, kan optræde efter injektioner.
transient neurological symptoms that may mimic ms exacerbations may occur following injections.

patienter, der lider af rrms, oplever attakker, der efterfølges af symptomfri perioder.
in rrms patients experience relapses followed by periods of recovery.

i begge undersøgelser medførte betaferon et fald (30 %) i antallet af kliniske attakker.
in both trials, betaferon showed a reduction in the number (30%) of clinical relapses.

attakvis remitterende ms er kendetegnet ved gentagne attakker (tilbagefald) af symptomer fra nervesystemet.
relapsing-remitting ms is characterised by repeated attacks (relapses) of nervous system symptoms.

betaferon kan nedsætte antallet af attakkerne og deres sværhedsgrad, og kan sinke sygdommens fremadskriden.
betaferon can reduce the number and severity of the attacks, and slow the progression of disability.